Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 3/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.34 |
| ▸ | PRKDC | P78527 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890607 | 0.92 | PLA2G2A (0.34) | PLA2G2APLA2G4APRKDCKDM4EATM | |
| SCHEMBL804982 | 0.91 | KDM4E (0.38) | PLA2G2APLA2G4AKDM4EATML3MBTL1 | |
| SCHEMBL9890231 | 0.91 | PLA2G2A (0.33) | PLA2G2APLA2G4APRKDCKDM4EATM | |
| SCHEMBL14733881 | 0.89 | PRKDC (0.31) | PLA2G2APLA2G4APRKDCHDAC4PLA2G10 | |
| SCHEMBL9890481 | 0.89 | KDM4E (0.37) | KDM4EATML3MBTL1HDAC4PGR | |
| SCHEMBL9890487 | 0.88 | PLA2G2A (0.31) | PLA2G2APLA2G4A | |
| SCHEMBL2628408 | 0.88 | HSP90AA1 (0.32) | KDM4EATML3MBTL1 | |
| SCHEMBL9890480 | 0.88 | L3MBTL1 (0.41) | KDM4EATML3MBTL1HDAC4TSPO | |
| SCHEMBL16744864 | 0.87 | PLA2G2A (0.34) | PLA2G2APLA2G4APRKDCKDM4EPGR | |
| SCHEMBL15946304 | 0.87 | PLA2G2A (0.32) | PLA2G2APLA2G4APRKDCKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130020563-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20130020563-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| US-8318323-B2 | Polycyclic compounds and organic electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318323-B2 | Polycyclic compounds and organic electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20120138915-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120138915-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20100012931-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130020563-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | KCNC1, EED, BMI1 | PLA2G2A 4239/4885PLA2G4A 4728/4885PRKDC 2162/4885 |
| US-20100012931-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | KCNC1, EED, BMI1 | PLA2G2A 4239/4885PLA2G4A 4728/4885PRKDC 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.